RGEN
REPLIGEN CORP
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$176.43
+0.58%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$177.82
From 52W high−9.32%
Volume769043.00
Market cap$11.20B
P/E (TTM)238.4x
P/S (TTM)14.3x
Div yield—
Key dataOct 19, 2026
Open
$177.82
From 52W high
−9.32%
Volume
769043.00
Market cap
$11.20B
ValuationView details →
P/E (Fwd)
72.6x
EV/EBITDA
63.4x
P/E (TTM)
238.4x
RSI (14)
49.7
MomentumView details →
1D Return
+0.58%
YTD Return
+7.84%
SummaryUpdated Jun 1, 2026
Repligen Corporation (NASDAQ:RGEN) is a leading bioprocessing technology company founded in 1981 and headquartered in Waltham, Massachusetts. The company went public in 1986 and has evolved from its origins as a biotechnology research company into a specialized provider of critical tools and technologies used in the manufacturing of biological drugs. Repligen serves the global biopharmaceutical industry by supplying essential equipment, consumables, and systems that enable the production of life-saving biologics including monoclonal antibodies, vaccines, cell and gene therapies, and other advanced therapeutic modalities.
Similar companies
Latest newsMore news →
Repligen announced that it will report its third-quarter 2026 financial results on October 27, 2026.6d agoRepligen Corporation completed its previously announced acquisition of BioLife Solutions, Inc., a developer and supplier of cell processing tools and services for the cell and gene therapy market.13d ago